2seventy bio Stock (NASDAQ:TSVT)
Previous Close
$5.00
52W Range
$2.29 - $5.30
50D Avg
$4.97
200D Avg
$4.05
Market Cap
$266.14M
Avg Vol (3M)
$1.46M
Beta
1.05
Div Yield
-
TSVT Company Profile
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.